Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 1/20 | 0.55 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.55 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.55 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.55 |
| ▸ | NUDT14 | O95848 | 1/20 | 0.53 |
| ▸ | NUDT5 | Q9UKK9 | 1/20 | 0.53 |
| ▸ | SRC | P12931 | 13/20 | 0.53 |
| ▸ | ABL1 | P00519 | 11/20 | 0.53 |
| ▸ | PIK3CD | O00329 | 11/20 | 0.53 |
| ▸ | PIK3CA | P42336 | 11/20 | 0.53 |
| ▸ | PIK3CB | P42338 | 11/20 | 0.53 |
| ▸ | PIK3CG | P48736 | 11/20 | 0.53 |
| ▸ | PRKDC | P78527 | 11/20 | 0.53 |
| ▸ | HCK | P08631 | 9/20 | 0.53 |
| ▸ | EGFR | P00533 | 9/20 | 0.53 |
| ▸ | MTOR | P42345 | 8/20 | 0.53 |
| ▸ | EPHB4 | P54760 | 8/20 | 0.53 |
| ▸ | PI4KB | Q9UBF8 | 4/20 | 0.53 |
| ▸ | KDR | P35968 | 7/20 | 0.52 |
| ▸ | PDE2A | O00408 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL130525 | 0.83 | PIK3CD (0.55) | NUDT14NUDT5SRCABL1PIK3CD | |
| SCHEMBL130752 | 0.80 | NUDT14 (0.74) | NUDT14NUDT5SRCABL1PIK3CD | |
| SCHEMBL129615 | 0.80 | SRC (0.79) | NUDT14NUDT5SRCABL1PIK3CD | |
| SCHEMBL18521742 | 0.79 | ERBB2 (0.46) | FGFR1FGFR2FGFR4FGFR3SRC | |
| SCHEMBL130481 | 0.79 | PIK3CD (0.71) | NUDT14NUDT5SRCABL1PIK3CD | |
| SCHEMBL130590 | 0.78 | SRC (0.73) | NUDT14NUDT5SRCABL1PIK3CD | |
| SCHEMBL21439870 | 0.78 | PIK3CD (0.53) | NUDT14NUDT5SRCABL1PIK3CD | |
| SCHEMBL31165921 | 0.78 | PIK3CD (0.53) | NUDT14NUDT5SRCABL1PIK3CD | |
| SCHEMBL129505 | 0.77 | PIK3CD (0.62) | FGFR1FGFR2FGFR4FGFR3NUDT14 | |
| SCHEMBL129879 | 0.77 | PIK3CD (0.57) | FGFR1FGFR2FGFR4FGFR3NUDT14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858907-B2 | Kinase modulators | RHIZEN PHARMACEUTICALS AG (CH) | 2024-01-02 | — | — | US | disclosed |
| US-10220035-B2 | Compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2019-03-05 | — | — | US | disclosed |
| US-20180110783-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2018-04-26 | — | — | US | disclosed |
| US-9775841-B2 | Compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2017-10-03 | — | — | US | disclosed |
| US-9775841-B2 | Compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2017-10-03 | — | — | US | disclosed |
| US-20160318890-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS AG (CH) | 2016-11-03 | — | — | US | disclosed |
| US-9421209-B2 | Kinase modulators | RHIZEN PHARMACEUTICALS SA (CH) | 2016-08-23 | — | — | US | disclosed |
| US-20150320752-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2015-11-12 | — | — | US | disclosed |
| US-20150174131-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS AG (CH) | 2015-06-25 | — | — | US | disclosed |
| US-9018375-B2 | Substituted chromenes as kinase modulators | RHIZEN PHARMACEUTICALS SA (CH) | 2015-04-28 | — | — | US | disclosed |
| US-20140080827-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS SA (CH) | 2014-03-20 | — | — | US | disclosed |
| US-8642607-B2 | 4H-chromen-4-one compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2014-02-04 | — | — | US | disclosed |
| US-20120289496-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2012-11-15 | — | — | US | disclosed |
| US-20120059001-A1 | NOVEL KINASE MODULATORS | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2012-03-08 | — | — | US | disclosed |
| US-20110118257-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS SA (CH) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150174131-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | FGFR1 2181/4885FGFR2 2829/4885FGFR4 3934/4885 |
| US-20150320752-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKCB | FGFR1 2006/4885FGFR2 2741/4885FGFR4 3732/4885 |
| US-20120289496-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKCB | FGFR1 2006/4885FGFR2 2741/4885FGFR4 3732/4885 |
| US-10220035-B2 | Compounds as modulators of protein kinases | PRKCA, PRKCH, PRKCE | FGFR1 1994/4885FGFR2 2730/4885FGFR4 3781/4885 |
| US-20180110783-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKCB | FGFR1 2006/4885FGFR2 2741/4885FGFR4 3732/4885 |
| US-20140080827-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | FGFR1 2181/4885FGFR2 2829/4885FGFR4 3934/4885 |
| US-20110118257-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | FGFR1 2181/4885FGFR2 2829/4885FGFR4 3934/4885 |
| US-11858907-B2 | Kinase modulators | RPS6KA1, RPS6KA2, PRKAR2A | FGFR1 1544/4885FGFR2 2332/4885FGFR4 4001/4885 |
| US-20160318890-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | FGFR1 2181/4885FGFR2 2829/4885FGFR4 3934/4885 |
| US-20120059001-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | FGFR1 2181/4885FGFR2 2829/4885FGFR4 3934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.